<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00603499</url>
  </required_header>
  <id_info>
    <org_study_id>2000-161-0027</org_study_id>
    <secondary_id>IMSS</secondary_id>
    <nct_id>NCT00603499</nct_id>
  </id_info>
  <brief_title>Magnesium and Metabolic Syndrome</brief_title>
  <official_title>Hypomagnesemia as a Risk Factor for Development of Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Mexicano del Seguro Social</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective : to test the BP lowering-effect of oral magnesium supplementation, as magnesium
      chloride (MgCl2) solution, 2.5 g daily, in uncomplicated hypertensive type 2 diabetic
      subjects with decreased serum magnesium levels Design : Randomised double blind placebo
      controlled trial. Setting : Outpatients with type 2 diabetes from Durango, city in northern
      Mexico Subjects : 82 subjects between 40 and 75 years of age with type 2 diabetes serum
      magnesium deficiency and uncomplicated hypertension.

      Interventions : During 4 months the intervention group received 2.5 gr of magnesium chloride
      (50 ml of a solution containing 50 gr of MgCl2 by 1000 ml of solution ). Controls received
      inert placebo.

      Main outcome measure: Change in blood pressure. Increase of serum magnesium Secondary
      outcomes measures: Changes in lipid profile
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in the systolic and diastolic blood pressures</measure>
    <time_frame>2 y</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average increase of serum magnesium levels Changes in lipid profile</measure>
    <time_frame>2 y</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>High Blood Pressure</condition>
  <condition>Hypomagnesemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Magnesium chloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Magnesium chloride</intervention_name>
    <description>Subjects in the intervention group received 2.5 gr of MgCl2 daily during 4 months, from a solution solution containing 50 gr of MgCl2 by 1000 ml.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects in the control group received inert placebo once per day during 4 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  Decreased serum magnesium levels

          -  Uncomplicated hypertension

          -  40 and 75 years of age

          -  Men and Women

        Exclusion Criteria:

          -  Chronic diarrhea

          -  Alcohol intake (equal or more than 30 g per day)

          -  Use of diuretics and/or calcium antagonists drugs

          -  Previous oral magnesium supplementation

          -  Ischemic diseases; AND

          -  Reduced renal function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martha Rodriguez-Moran, MD, MSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Mexicano del Seguro Social</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biomedical Research Unit</name>
      <address>
        <city>Durango</city>
        <zip>34067</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2008</study_first_posted>
  <last_update_submitted>January 16, 2008</last_update_submitted>
  <last_update_submitted_qc>January 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Fernando Guerrero-Romero</name_title>
    <organization>Biomedical Research Unit, Instituto Mexicano del Seguro Social</organization>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Hypomagnesemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

